BostonGene and the Parker Institute for Cancer Immunotherapy Collaborate to Generate Comprehensive Longitudinal Multi-Omic Data for Predicting Immunotherapy Outcomes
30 April 2024 - 10:55PM
Business Wire
Study to correlate genetic variation and
peripheral blood signatures with immunotherapy response, resistance
and toxicity
BostonGene, a leading provider of AI-driven molecular and immune
profiling solutions, and the Parker Institute for Cancer
Immunotherapy (PICI), a network of the largest concentration of
immuno-oncology (IO) expertise in the world, announced today the
launch of a collaboration aimed at uncovering molecular mechanisms
underlying IO treatment response and treatment-related toxicity in
advanced cancer patients and discovering actionable blood-based
biomarkers.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240430479822/en/
BostonGene will analyze longitudinal blood samples from PICI’s
RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients
Interrogated by Harmonized Molecular Datasets) program, a
prospective study of approximately 1,200 pan-cancer patients on
standard of care immune checkpoint inhibitor treatment regimens.
BostonGene’s revolutionary immunoprofiling incorporates flow
cytometry and RNA-sequencing to track changes in the peripheral
blood, which will be correlated with genetic variations from
germline DNA testing to uncover blood-based signatures with
immunotherapy response, resistance and toxicity.
“PICI’s mission-focused collaboration with BostonGene is a
significant step toward unlocking the potential of blood-based
biomarkers to advance personalized immunotherapy,” said Tarak Mody,
PhD, Chief Business Officer at PICI. "Through the generation of
large multi-omic datasets and machine learning, we aim to provide
the PICI Network and our partners with improved patient selection
strategies and valuable insights that can accelerate discovery,
target validation and clinical research.”
"BostonGene's AI-driven solutions combined with PICI's
unparalleled network of immuno-oncology expertise promise to
redefine how we approach advanced cancer treatment. Together, we're
pioneering the search for blood-based biomarkers," said Nathan
Fowler, MD, Chief Medical Officer at BostonGene.
About BostonGene Corporation
BostonGene has a mission to provide transformative,
AI-integrated molecular analytics and biomarker discovery for
precision matching of therapies to improve the lives of patients
living with cancer and other immune-related diseases. BostonGene’s
concierge-service model provides customized client solutions using
a multi-omic approach prioritized for real-world impact to optimize
standard-of-care therapies, accelerate research and provide
cost-effective, measurable data-driven results. BostonGene’s tests
reveal key drivers of each patient’s unique disease profile,
including an in-depth profile of the immune microenvironment,
actionable mutations, biomarkers of response to diverse therapies,
and recommended therapies. Through these comprehensive analyses,
BostonGene’s tests generate a personalized roadmap for therapeutic
decision-making for each patient. For more information, visit
BostonGene at http://www.BostonGene.com.
About the Parker Institute for Cancer Immunotherapy
The Parker Institute for Cancer Immunotherapy (PICI) is
radically changing how cancer research is done. Founded in 2016
through a $250 million gift from Silicon Valley entrepreneur and
philanthropist Sean Parker, the San Francisco-based nonprofit is an
unprecedented collaboration between the country’s leading
immunotherapy researchers and cancer centers. PICI Network research
institutions include Stanford Medicine; the University of
California, Los Angeles; the University of California, San
Francisco; the University of Pennsylvania; Dana-Farber Cancer
Institute; Gladstone Institutes; and Weill Cornell Medicine. PICI
also supports top researchers at other institutions, including The
University of Texas MD Anderson Cancer Center, Memorial Sloan
Kettering Cancer Center, City of Hope, Fred Hutchinson Cancer
Research Center, Icahn School of Medicine at Mount Sinai, Institute
for Systems Biology and Washington University School of Medicine in
St. Louis. By forging alliances with academic, industry and
nonprofit partners, PICI makes big bets on bold research to fulfill
its mission: to accelerate the development of breakthrough
immunotherapies to turn all cancers into curable diseases. Find out
more at parkerici.org and follow us on LinkedIn, X (formerly
Twitter) @parkerici, and on Spotify.
About RADIOHEAD
The RADIOHEAD (Resistance Drivers for Immuno-Oncology Patients
Interrogated by Harmonized Molecular Datasets) program is a
pan-tumor, prospective cohort study of 1000+ immunotherapy naive
individuals on standard of care immune checkpoint inhibitor (CPI)
treatment regimens. This study captured a comprehensive profile of
each participant by collecting blood samples and clinical features
at pretreatment, early on-treatment, and late timepoints from 52
community oncology clinics across the United States. If
participants experienced immune-related adverse events, additional
samples were collected upon presentation and in follow-up visits.
In all, over 3700 longitudinal samples were collected, with a focus
on major IO indications such as non-small cell lung cancer (~1400
samples) and malignant melanoma (~500 samples). Pairing
comprehensive multi-omic profiling of these longitudinal samples
with associated demographic and clinical outcomes provides an
opportunity to identify clinically actionable mechanisms for CPI
resistance and adverse events, discover targets for combination
therapies and post-CPI treatment, and inform system biology
approaches to elucidate disease pathways.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240430479822/en/
Media: BostonGene Erin O’Reilly +1 617-283-2285
Erin.Oreilly@BostonGene.com Parker Institute for Cancer
Immunotherapy (PICI) Eric McKeeby +1 646-522-4605
emckeeby@parkerici.org